Antibody-based inhibitors of HIV infection (Q36446952)

14 August 2017

1 reference

title

Antibody-based inhibitors of HIV infection (English)

1 reference

14 August 2017

Vidita Choudhry

1 reference

14 August 2017

Mei-Yun Zhang

1 reference

14 August 2017

Dimana Dimitrova

1 reference

14 August 2017

Ponraj Prabakaran

1 reference

14 August 2017

Antony S Dimitrov

1 reference

14 August 2017

Timothy R Fouts

1 reference

14 August 2017

Dimiter S Dimitrov

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 May 2006

1 reference

Expert Opinion on Biological Therapy

14 August 2017

published in

1 reference

14 August 2017

1 reference

14 August 2017

1 reference

14 August 2017

page(s)

523-531

1 reference

Passive antibody therapy for infectious diseases

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

A passive immunotherapy, (PE)HRG214, in patients infected with human immunodeficiency virus: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

Neutralizing antibody responses to HIV: role in protective immunity and challenges for vaccine design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

Identifying epitopes of HIV-1 that induce protective antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

Antibodies: can they protect against HIV infection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

The prospects for vaccines against HIV-1: more than a field of long-term nonprogression?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

HIV vaccine design and the neutralizing antibody problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

Virus entry: molecular mechanisms and biomedical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

Antibody neutralization and escape by HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

The antigenic structure of the HIV gp120 envelope glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

Broadly cross-reactive HIV neutralizing human monoclonal antibody Fab selected by sequential antigen panning of a phage display library

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

A phase I/IIA clinical study with a chimeric mouse-human monoclonal antibody to the V3 loop of human immunodeficiency virus type 1 gp120.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

A human monoclonal antibody to HIV-1 gp41 with neutralizing activity against diverse laboratory isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

The isolation and nucleotide sequence of a cDNA encoding the T cell surface protein T4: a new member of the immunoglobulin gene family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

The biology of chemokines and their receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

Adaptation to blockade of human immunodeficiency virus type 1 entry imposed by the anti-CCR5 monoclonal antibody 2D7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

Identification of a linear peptide recognized by monoclonal antibody 2D7 capable of generating CCR5-specific antibodies with human immunodeficiency virus-neutralizing activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

Generation and characterization of a recombinant human CCR5-specific antibody. A phage display approach for rabbit antibody humanization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

Co-receptor antagonists as HIV-1 entry inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

Improved breadth and potency of an HIV-1-neutralizing human single-chain antibody by random mutagenesis and sequential antigen panning

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

Antigenic conservation and immunogenicity of the HIV coreceptor binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

Neutralization of human immunodeficiency virus type 1 by sCD4-17b, a single-chain chimeric protein, based on sequential interaction of gp120 with CD4 and coreceptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

Antiviral effects of CD4 derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

Phase 1 study of recombinant human CD4-immunoglobulin G therapy of patients with AIDS and AIDS-related complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

Biochemical and biological characterization of a dodecameric CD4-Ig fusion protein: implications for therapeutic and vaccine strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

Structural flexibility and functional valence of CD4-IgG2 (PRO 542): potential for cross-linking human immunodeficiency virus type 1 envelope spikes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

The appealing story of HIV entry inhibitors : from discovery of biological mechanisms to drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

Identification of a novel CD4i human monoclonal antibody Fab that neutralizes HIV-1 primary isolates from different clades

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

Phase I Study of a Human Monoclonal Antibody Directed against the CD4-Binding Site of HIV Type 1 Glycoprotein 120

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

Monoclonal antibody hNM01 in HIV-infected patients: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

HIV-1 neutralization by chimeric CD4-CG10 polypeptides fused to human IgG1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

Expression and Characterization of CD4-IgG2, a Novel Heterotetramer That Neutralizes Primary HIV Type 1 Isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

Inhibition of HIV type 1 infection with a RANTES-IgG3 fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.523

21 January 2018

Identifiers

DOI

10.1517/14712598.6.5.523

1 reference

14 August 2017

1 reference